Friday, June 15, 2018 6:27:11 AM
when they found responders in Phase 2a they did Gut Bio, Hired Computer Firm to run tens of millions of calculations as to WHY they were responding, brought in DNA team to find DNA expressions and biomarkers..
THEN they applied for three Phase 2/3 Trials in Three Indications..
Trials havent started yet.and shareholders have paid the price for waiting..
but the purpose of Phase 3 is to WIN not get close..
I think VTVT has something otherwise 88 people wold not hav ecrushed Placebo group..it svery exciting..
They should follow Anavex Lead, go back, get your data points and redo a new Phase 3 with proper criteria to support Low Plasma..
It may take a year..but Dementia not going anywhere..
BP would KILL to have 88 Patients BEAT SOC at 12 months..KILL
Recent VTVT News
- CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT • PR Newswire (US) • 03/19/2024 12:30:00 PM
- vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/13/2024 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:47:37 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 03/06/2024 12:52:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 01:04:31 PM
- vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes • GlobeNewswire Inc. • 03/04/2024 01:00:00 PM
- vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference • GlobeNewswire Inc. • 03/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:26:55 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/28/2024 02:14:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 01:08:30 PM
- vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund • GlobeNewswire Inc. • 02/28/2024 01:00:00 PM
- CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE • PR Newswire (US) • 02/22/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:26:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:28:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:21:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:23:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 01:22:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 01:19:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:31 PM
- vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/09/2023 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:20:16 PM
- vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 01:00:00 PM
- vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer • GlobeNewswire Inc. • 11/02/2023 12:00:54 PM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM